{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T21:41:56Z","timestamp":1786398116402,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1007\/s11906-008-0052-8","type":"journal-article","created":{"date-parts":[[2008,10,29]],"date-time":"2008-10-29T17:12:34Z","timestamp":1225300354000},"page":"276-285","source":"Crossref","is-referenced-by-count":19,"title":["Race-based therapeutics"],"prefix":"10.1007","volume":"10","author":[{"given":"Clyde W.","family":"Yancy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,10,30]]},"reference":[{"key":"52_CR1","first-page":"75","volume":"21","author":"D.R. Williams","year":"2000","unstructured":"Williams DR, Rucker TD: Understanding and addressing racial disparities in health care. Health Care Financ Review 2000, 21:75\u201390.","journal-title":"Health Care Financ Review"},{"key":"52_CR2","volume-title":"2003 Heart Disease and Stroke Statistics-Update","author":"American Heart Association.","year":"2002","unstructured":"American Heart Association. 2003 Heart Disease and Stroke Statistics-Update. Dallas TX: American Heart Association; 2002."},{"key":"52_CR3","volume-title":"Heart Disease and Stroke Statistics\u20142008 Update","author":"American Heart Association.","year":"2008","unstructured":"American Heart Association. Heart Disease and Stroke Statistics\u20142008 Update. Dallas, TX: American Heart Association; 2008."},{"key":"52_CR4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1054\/jcaf.2000.17610","volume":"6","author":"C.W. Yancy","year":"2000","unstructured":"Yancy CW: Heart failure in African Americans: a cardiovascular engima. J Card Fail 2000, 6:183\u2013186.","journal-title":"J Card Fail"},{"key":"52_CR5","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","volume":"42","author":"A.V. Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206\u20131252.","journal-title":"Hypertension"},{"key":"52_CR6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jama.290.2.199","volume":"290","author":"I. Hajjar","year":"2003","unstructured":"Hajjar I, Kotchen TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988\u20132000. JAMA 2003, 290:199\u2013206.","journal-title":"JAMA"},{"key":"52_CR7","doi-asserted-by":"crossref","unstructured":"The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997, 157:2413\u20132446.","DOI":"10.1001\/archinte.1997.00440420033005"},{"key":"52_CR8","doi-asserted-by":"crossref","unstructured":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998, 317:703\u2013713. [Published erratum appears in BMJ 1999, 318:29.]","DOI":"10.1136\/bmj.317.7160.703"},{"key":"52_CR9","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"ALLHAT OfficersCoordinators for the ALLHAT Collaborative Research Group.","year":"2002","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981\u20132997. [Published errata appears in JAMA 2003, 289:178 and JAMA 2004, 291:2196.]","journal-title":"JAMA"},{"key":"52_CR10","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","volume":"288","author":"J.T. Wright","year":"2002","unstructured":"Wright JT, Bakris G, Greene T: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA 2002, 288:2421\u20132431.","journal-title":"JAMA"},{"key":"52_CR11","first-page":"40","volume":"91","author":"L.M. Prisant","year":"1999","unstructured":"Prisant LM, Neutel JM, Ferdinand K, et al.: Low-dose combination therapy as first-line hypertension treatment for blacks and nonblacks. J Natl Med Assoc 1999, 91:40\u201348.","journal-title":"J Natl Med Assoc"},{"key":"52_CR12","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/archinte.163.5.525","volume":"163","author":"J.G. Douglas","year":"2003","unstructured":"Douglas JG, Bakris GL, Epstein M, et al.: Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003, 163:525\u2013541.","journal-title":"Arch Intern Med"},{"key":"52_CR13","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1161\/CIRCULATIONAHA.105.553370","volume":"112","author":"S.A. Hunt","year":"2005","unstructured":"Hunt SA, Abraham WT, Chin MH, et al.: ACC\/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112:e154\u2013e235.","journal-title":"Circulation"},{"key":"52_CR14","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM199902253400804","volume":"340","author":"D.L. Dries","year":"1999","unstructured":"Dries DL, Exner DV, Gersh BJ, et al.: Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999, 340:609\u2013616.","journal-title":"N Engl J Med"},{"issue":"7B","key":"52_CR15","doi-asserted-by":"crossref","first-page":"3i","DOI":"10.1016\/j.amjcard.2005.07.028","volume":"96","author":"C.W. Yancy","year":"2005","unstructured":"Yancy CW: Heart failure in African Americans. Am J Cardiol 2005, 96(7B):3i\u201312i.","journal-title":"Am J Cardiol"},{"key":"52_CR16","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","volume":"351","author":"A.L. Taylor","year":"2004","unstructured":"Taylor AL, Ziesche S, Yancy C, et al.: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004, 351:2049\u20132057.","journal-title":"N Engl J Med"},{"key":"52_CR17","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJM200105033441802","volume":"344","author":"D.V. Exner","year":"2001","unstructured":"Exner DV, Dries DL, Domanski MJ, et al.: Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001, 344:1351\u20131357.","journal-title":"N Engl J Med"},{"key":"52_CR18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"S. Yusuf","year":"2000","unstructured":"Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145\u2013153. [Published errata appear in N Engl J Med 2000, 342:748 and N Engl J Med 2000, 342:1376.]","journal-title":"N Engl J Med"},{"key":"52_CR19","first-page":"1667","volume":"345","author":"J.N. Cohn","year":"2000","unstructured":"Cohn JN, Tognoni G, Glazer R, Spoprmann D: Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators. Eur J Heart Fail 2000, 345:1667\u20131675.","journal-title":"Eur J Heart Fail"},{"key":"52_CR20","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","volume":"362","author":"M.A. Pfeffer","year":"2003","unstructured":"Pfeffer MA, Swedberg K, Granger CB, et al.; CHARM Investigators and Committees: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM Overall Programme. Lancet 2003, 362:759\u2013766.","journal-title":"Lancet"},{"key":"52_CR21","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.HYP.0000236119.96301.f2","volume":"48","author":"S. Julius","year":"2006","unstructured":"Julius S, Weber M, Kjeldsen S, et al.: The Valsartan Antihypertension Long Term Use Evaluation [VALUE] Trial: outcomes in patients receiving monotherapy. Hypertension 2006, 48:385\u2013391.","journal-title":"Hypertension"},{"key":"52_CR22","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/S0735-1097(03)00262-6","volume":"41","author":"P.G. Shekelle","year":"2003","unstructured":"Shekelle PG, Rich MW, Morton SC, et al.: Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003, 41:1529\u20131538.","journal-title":"J Am Coll Cardiol"},{"key":"52_CR23","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJM200105313442202","volume":"344","author":"The Beta-Blocker Evaluation of Survival Trial Investigators","year":"2001","unstructured":"The Beta-Blocker Evaluation of Survival Trial Investigators: A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001, 344:1659\u20131667.","journal-title":"N Engl J Med"},{"key":"52_CR24","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1161\/01.CIR.0000016050.79810.18","volume":"105","author":"P. Andreka","year":"2002","unstructured":"Andreka P, Aiyar N, Olson LC, et al.: Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation 2002, 105:2429\u20132434.","journal-title":"Circulation"},{"key":"52_CR25","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJM200105033441803","volume":"344","author":"C.W. Yancy","year":"2001","unstructured":"Yancy CW, Fowler MB, Colucci WS, et al.: Race and the response to adrenergic blockade with carvedilol in patients with heart failure. N Engl J Med 2001, 344:1358\u20131365.","journal-title":"N Engl J Med"},{"issue":"SupplII","key":"52_CR26","first-page":"II","volume":"104","author":"P. Carson","year":"2001","unstructured":"Carson P, Fowler MB, Mohacsi P, et al.: Effect of carvedilol in black patients with severe chronic heart failure: results of the COPERNICUS Study [abstract]. Circulation 2001, 104(Suppl II):II\u2013754.","journal-title":"Circulation"},{"key":"52_CR27","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","volume":"353","author":"Effect of metoprolol CR\/XL in chronic heart failure","year":"1999","unstructured":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001\u20132007.","journal-title":"Lancet"},{"key":"52_CR28","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1161\/hc4301.098254","volume":"104","author":"Z.J. Zheng","year":"2001","unstructured":"Zheng ZJ, Croft JB, Giles WH, Mensah GA: Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001, 104:2158\u20132163.","journal-title":"Circulation"},{"issue":"Suppl5","key":"52_CR29","first-page":"V11","volume":"22","author":"A. Hjalmarson","year":"1999","unstructured":"Hjalmarson A: Prevention of sudden cardiac death with beta blockers. Clin Cardiol 1999, 22(Suppl 5):V11\u2013V15.","journal-title":"Clin Cardiol"},{"key":"52_CR30","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jacc.2004.09.076","volume":"45","author":"J. McMurray","year":"2005","unstructured":"McMurray J, Kober L, Robertson M, et al.: Antiarrhythmic effect of carvedilol after acute myocardial infarction Results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005, 45:525\u2013530.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl1","key":"52_CR31","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/S1071-9164(03)00311-7","volume":"9","author":"W.T. Abraham","year":"2003","unstructured":"Abraham WT, Massie BM, Franciosa JA, et al.: Tolerability, safety, and efficacy of beta-blockade in black patients with heart failure in the community setting: Insights from a large prospective beta-blocker registry. Presented at the Heart Failure Society of America 7th Annual Scientific Meeting; September 22, 2003; Las Vegas, NV [abstract 348]. J Card Fail 2003, 9(Suppl 1):S94.","journal-title":"J Card Fail"},{"key":"52_CR32","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","volume":"314","author":"J.N. Cohn","year":"1986","unstructured":"Cohn JN, Archibald MP, Ziesche S, et al.: Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986, 314:1547\u20131552","journal-title":"N Engl J Med"},{"key":"52_CR33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1378\/chest.73.1.8","volume":"73","author":"G.L. Pierpont","year":"1978","unstructured":"Pierpont GL, Cohn JN, Franciosa JA, et al.: Combined oral hydralazine-nitrate therapy in left ventricular failure: hemodynamic equivalency to sodium nitroprusside. Chest 1978, 73:8\u201313","journal-title":"Chest"},{"key":"52_CR34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","volume":"325","author":"J.N. Cohn","year":"1991","unstructured":"Cohn JN, Johnson G, Ziesche S, et al.: A comparison of enalapri with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325:303\u2013310.","journal-title":"N Engl J Med"},{"key":"52_CR35","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S1071-9164(99)90001-5","volume":"5","author":"P. Carson","year":"1999","unstructured":"Carson P, Ziesche S, Johnson G, et al.: Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail 1999; 5:178\u2013187.","journal-title":"J Card Fail"},{"key":"52_CR36","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.cardfail.2006.06.274","volume":"12","author":"C.W. Yancy","year":"2006","unstructured":"Yancy CW, Ghali JK, Braman VM, et al.: Results of the extension to A-HeFT [X-A-HeFT] support the continued safety and tolerability of fixed dose isosorbide dinitrate\/hydralazine. J Card Fail 2006, 12:S80.","journal-title":"J Card Fail"},{"key":"52_CR37","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/01.HYP.0000024571.69634.ED","volume":"40","author":"D.F. Kahn","year":"2002","unstructured":"Kahn DF, Duffy SJ: Effects of black race on forearm resistance vessel function. Hypertension 2002, 40:195\u2013201.","journal-title":"Hypertension"},{"key":"52_CR38","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1161\/01.HYP.31.6.1235","volume":"31","author":"C. Cardillo","year":"1998","unstructured":"Cardillo C, Kilcoyne CM, Cannon RO, et al.: Racial differences in nitric oxide-mediated vasodilator response to mental stress in the forearm circulation. Hypertension 1998, 31:1235\u20131239.","journal-title":"Hypertension"},{"key":"52_CR39","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1161\/01.CIR.0000129087.81352.7A","volume":"109","author":"L. Kalinowski","year":"2004","unstructured":"Kalinowski L, Dobrucki, IT, Tomasian D, et al.: Race-specific differences in endothelial function: predisposition of African Americans to vascular disease. Circulation 2004, 109:2511\u20132517.","journal-title":"Circulation"},{"key":"52_CR40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1161\/01.RES.0000129569.07667.89","volume":"94","author":"S.D. Prabhu","year":"2004","unstructured":"Prabhu SD: Nitric oxide protects against pathological ventricular remodeling: reconsideration of the role of NO in the failing heart. Circ Res 2004, 94:115\u2013157.","journal-title":"Circ Res"},{"key":"52_CR41","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1056\/NEJMe048269","volume":"351","author":"J.M. Hare","year":"2004","unstructured":"Hare JM: Nitroso-redox balance in the cardiovascular system. N Engl J Med 2004, 351:2112\u20132114.","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"52_CR42","doi-asserted-by":"crossref","first-page":"13i","DOI":"10.1016\/j.amjcard.2005.07.029","volume":"96","author":"T. Malinski","year":"2005","unstructured":"Malinski T: Understanding nitric oxide physiology in the heart: a nanomedical approach. Am J Cardiol 2005, 96(Suppl):13i\u201324i.","journal-title":"Am J Cardiol"},{"key":"52_CR43","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1023\/A:1020706316429","volume":"7","author":"K.C. Wollert","year":"2002","unstructured":"Wollert KC, Drexler H: Regulation of cardiac remodeling by nitric oxide: focus on cardiac myocyte hypertrophy and apoptosis. Heart Fail Rev 2002, 7:317\u2013325.","journal-title":"Heart Fail Rev"},{"key":"52_CR44","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1161\/01.RES.0000126497.38281.23","volume":"94","author":"S. Janssens","year":"2004","unstructured":"Janssens S, Pokreisz P, Schoonjans L, et al.: Cardiomyocytespecific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res 2004, 94:1256\u20131262.","journal-title":"Circ Res"},{"key":"52_CR45","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jacc.2006.07.030","volume":"48","author":"D.M. McNamara","year":"2007","unstructured":"McNamara DM, Tam SW, Sabolinski ML, et al.: Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial. J Am Coll Cardiol 2007, 48:1277\u20131282.","journal-title":"J Am Coll Cardiol"},{"key":"52_CR46","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1056\/NEJM199702133360706","volume":"336","author":"E.D. Peterson","year":"1997","unstructured":"Peterson ED, Shaw LK, DeLong ER, et al.: Racial variation in the use of coronary-revascularization procedures. Are the differences real? Do they matter? N Engl J Med 1997, 336:480\u2013486.","journal-title":"N Engl J Med"},{"key":"52_CR47","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/01.HYP.37.2.739","volume":"37","author":"S.T. Turner","year":"2001","unstructured":"Turner ST, Schwartz GL, Chapman AB, Boerwinkle E: C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension. 2001, 37:739\u2013743.","journal-title":"Hypertension"},{"key":"52_CR48","first-page":"3479","volume":"97","author":"M. Suthanthiran","year":"2000","unstructured":"Suthanthiran M, Li B, Song JO, et al.: Transforming growth factor-beta1 hyperexpression in African-American hypertensives: a novel mediator of hypertension and\/or target organ damage. Proc Natl Acad Sci 2000, 97:3479\u20133484.","journal-title":"Proc Natl Acad Sci"},{"key":"52_CR49","doi-asserted-by":"crossref","first-page":"12670","DOI":"10.1074\/jbc.274.18.12670","volume":"274","author":"D.A. Mason","year":"1999","unstructured":"Mason DA, Moore JD, Green SA, Liggett SB: A gain-offunction polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem. 1999, 274:12670\u201312674.","journal-title":"J Biol Chem"},{"key":"52_CR50","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1056\/NEJMoa020803","volume":"347","author":"K.M. Small","year":"2002","unstructured":"Small KM, Wagoner LE, Levin AM, et al.: Synergistic polymorphisms of beta1-and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002, 347:1135\u20131142.","journal-title":"N Engl J Med"},{"key":"52_CR51","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1527-5299.2004.03855.x","volume":"10","author":"D. McNamara","year":"2004","unstructured":"McNamara D: Pharmacogenetics in heart failure: genomic markers of endothelial and neurohumoral function. Congest Heart Fail 2004, 10:302\u2013308.","journal-title":"Congest Heart Fail"},{"key":"52_CR52","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/j.jacc.2004.08.048","volume":"44","author":"D.M. McNamara","year":"2004","unstructured":"McNamara DM, Holubkov R, Postava L, et al.: Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol 2004, 44:2019\u20132026.","journal-title":"J Am Coll Cardiol"},{"key":"52_CR53","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1161\/01.CIR.0000060540.93836.AA","volume":"107","author":"D.M. McNamara","year":"2003","unstructured":"McNamara DM, Holubkov R, Postava L, et al.: Effect of the Asp298 variant of endothelial nitric oxide synthase on survival for patients with congestive heart failure. Circulation 2003, 107:1598\u20131602.","journal-title":"Circulation"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-008-0052-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-008-0052-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-008-0052-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:14:21Z","timestamp":1559434461000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-008-0052-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["52"],"URL":"https:\/\/doi.org\/10.1007\/s11906-008-0052-8","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}